Association between bosutinib treatment and pulmonary arterial hypertension in patients with chronic myeloid leukaemia

Cases of pulmonary arterial hypertension (PAH) were reported after bosutinib exposure, most often in patients with pre-existing dasatinib-induced PAH, which relapsed following switch to bosutinib. Whether bosutinib by itself could induce PAH remains unclear. We retrospectively analysed incident cases of PAH in patients treated with bosutinib between 2013 and 2024, as well as their exposure to other BCR ABL tyrosine kinase inhibitors, using data from the French pulmonary hypertension (PH) registry and the French national health care database. 12 cases of bosutinib-associated PAH in patients with chronic myeloid leukaemia were identified in the PH registry (8 females; median age, 67 years), 11 of whom had prior dasatinib exposure, with history of dasatinib-induced cardiopulmonary complications in 10/11 cases including PAH ( n = 4), pleural or pericardial effusion ( n = 4) or both ( n = 2). Only 1 case occurred in a patient with severe chronic obstructive pulmonary disease and no prior dasatinib exposure. Despite often severe clinical (New York Heart Association functional class III or IV in 8 patients) and haemodynamic (median pulmonary vascular resistance, 5.9 [min-max, 2.2–11.9] Wood Units) involvement at PAH diagnosis, significant improvements were observed after bosutinib discontinuation, combined with PAH approved therapies in most cases. Sixteen cases of bosutinib-associated PAH were identified from the SNDS database (2.37 [95% confidence interval, 1.35 to 3.85] per 1000 person-years), including 13 with prior dasatinib exposure. Our findings do not provide evidence that bosutinib alone can induce de novo PAH, but support a role for bosutinib in triggering or worsening pulmonary vascular injury in patients previously exposed to dasatinib. Physicians should be aware of this rare but severe complication of bosutinib for close monitoring and appropriate management, particularly in patients with prior history of dasatinib induced-cardiopulmonary complications.

Authors

Institutions

Publication Details

Journal
Respiratory Research
Published
2026-11-18
DOI
https://doi.org/10.1186/s12931-026-03995-7
Primary Topic
Pulmonary Hypertension Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Association between bosutinib treatment and pulmonary arterial hypertension in patients with chronic myeloid leukaemia

Clément Jambon-Barbara, Charles Khouri, Marianne Riou, Ségolène Turquier et al.
Respiratory Research
Pulmonary Hypertension Research and Treatments
article

Association between bosutinib treatment and pulmonary arterial hypertension in patients with chronic myeloid leukaemia

Clément Jambon-Barbara, Charles Khouri, Marianne Riou, Ségolène Turquier, Martine Reynaud‐Gaubert, Marie‐Camille Chaumais, Rose Esnaud, J. Iván, Léon Genecand, Nicolas Favrolt, David Montani, Marc J.C. Humbert, Olivier Sitbon, Frédéric Gagnadoux, Amélie Servettaz, Pascal Magro, Nicolas Lamblin, Elise Noel Salvina
article en

Abstract

Cases of pulmonary arterial hypertension (PAH) were reported after bosutinib exposure, most often in patients with pre-existing dasatinib-induced PAH, which relapsed following switch to bosutinib. Whether bosutinib by itself could induce PAH remains unclear. We retrospectively analysed incident cases of PAH in patients treated with bosutinib between 2013 and 2024, as well as their exposure to other BCR ABL tyrosine kinase inhibitors, using data from the French pulmonary hypertension (PH) registry and the French national health care database. 12 cases of bosutinib-associated PAH in patients with chronic myeloid leukaemia were identified in the PH registry (8 females; median age, 67 years), 11 of whom had prior dasatinib exposure, with history of dasatinib-induced cardiopulmonary complications in 10/11 cases including PAH ( n = 4), pleural or pericardial effusion ( n = 4) or both ( n = 2). Only 1 case occurred in a patient with severe chronic obstructive pulmonary disease and no prior dasatinib exposure. Despite often severe clinical (New York Heart Association functional class III or IV in 8 patients) and haemodynamic (median pulmonary vascular resistance, 5.9 [min-max, 2.2–11.9] Wood Units) involvement at PAH diagnosis, significant improvements were observed after bosutinib discontinuation, combined with PAH approved therapies in most cases. Sixteen cases of bosutinib-associated PAH were identified from the SNDS database (2.37 [95% confidence interval, 1.35 to 3.85] per 1000 person-years), including 13 with prior dasatinib exposure. Our findings do not provide evidence that bosutinib alone can induce de novo PAH, but support a role for bosutinib in triggering or worsening pulmonary vascular injury in patients previously exposed to dasatinib. Physicians should be aware of this rare but severe complication of bosutinib for close monitoring and appropriate management, particularly in patients with prior history of dasatinib induced-cardiopulmonary complications.

Respiratory Research
Université Claude Bernard Lyon 1 (FR), Inserm (FR), Aix-Marseille Université (FR), Université de Lille (FR), Université Paris-Saclay (FR), Centre Hospitalier Universitaire de Grenoble (FR), Institut Pasteur de Lille (FR), Centre Hospitalier Universitaire de Lille (FR), Centre Hospitalier Universitaire de Toulouse (FR), Assistance Publique Hôpitaux de Marseille (FR), Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (FR), Centre Hospitalier Universitaire de Tours (FR), Assistance Publique – Hôpitaux de Paris (FR), Hôpital Bretonneau (FR), Hospices Civils de Lyon (FR), Centre Hospitalier Universitaire de Reims (FR), Hypertension pulmonaire : physiopathologie et innovation thérapeutique (FR), Centre Hospitalier Universitaire d'Angers (FR), Hôpital Nord (FR), CHU Dijon Bourgogne (FR), Hôpital Louis Pradel (FR), Hôpitaux Universitaires de Strasbourg (FR), Bicêtre Hospital (FR), Approches épidémiologiques et moléculaires intégratives visant à améliorer la compréhension des maladies chroniques liées au vieillissement (FR), Université Bourgogne Europe (FR), Université Grenoble Alpes (FR)
Good health and well-being
Pulmonary Hypertension Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon